Key result
JenaValve Trilogy shows promising outcomes for native aortic regurgitation in early clinical data.
Real-world study evaluates JenaValve Trilogy transcatheter aortic valve implantation in Asian patients with native aortic regurgitation, highlighting device utility beyond pivotal clinical trials.
Transcatheter aortic valve implantation (TAVI) with the dedicated JenaValve Trilogy system has shown promising results in the ALIGN-AR pivotal trial for patients with symptomatic native aortic regurgitation (AR) at high surgical risk. Real-world data outside the United States, particularly from Asian populations, remain limited.
No takes yet. Share an insight, caveat, or question.
Alvin Hon Yeung Ko (2026) studied this question. Transcatheter aortic valve implantation with the JenaValve Trilogy system has shown promising results for native aortic regurgitation, though real-world Asian data remains limited.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: